What is claimed is:

1. An ophthalmic pharmaceutical composition for controlling and lowering intraocular pressure comprising a basic active, an anionic mucomimetic polymer, and a cation exchange resin.

- 2. The composition according to Claim 1 wherein the composition is an aqueous dispersion.
- 3. An ophthalmic pharmaceutical composition for controlling and lowering intraocular pressure as an aqueous dispersion comprising a basic active, an afforic mucomimetic polymer, and a finely divided cation exchange resin.
- 4. The composition according to Claim 3 wherein the basic active is betaxolol.
- 5. The composition according to Claim 3 wherein the basic active is timolol.
- 6. The composition of Claim 3 wherein the basic active is selected from pilocarpine, epinephrine, proepinephrine, norepinephrine, pronorepinephrine, clonidine, p-aminoclonidine, p-acetoamidoclonidine, or a beta-blocker selected from betaxolol, timolol, acebutolol, alprenolol, atenolol, bevantolol, bucomolol, bupranolol, butidrine, bunitolol, bunolol, butocrolol, butoamine, carazolol, carteolol, exaprolol, indenolol, iprocrolol, labetolol, mepindolol, metiprarolol, metaprolol, moprolol, nadolol, nifenalol, oxprenolol, pamatolol, paragolol, penbutolol, pindolol, practolol, procinolol, propethalol, propranolol, sotalol, tazolol, tiprenolol, tolamolol, toliprolol, befunolol, esmalol, hepunolol, celiprolol, azotinolol, diacetalol, acebutolol, salbutanol and isoxaprolol.

War War

7. A method of treatment for controlling intraocular pressure comprising administering a composition which includes a basic active, an anionic mucomimetic polymer and a cation exchange resint top cally to the affected eye.

8. The method according to claim 7 wherein the composition is an aqueous dispersion.

9. The method according to Claim 8/wherein the cation exchange resin is finely divided.

- 10. The method according to Claim 9 wherein the basic active is betaxolol.
- 11. The method according to Claim 9 wherein the basic active is timolol.
- 12. The method according to Clarm 9 wherein the basic active is selected from pilocarpine, epinephrine, proepinephrine, norepinephrine, pronorepinephrine, clonidine, p-aminoclonidine, p-acetoamidoclonidine, or a beta-blocker selected from betaxolol, timolol, acebutolol, alprenolol, atenolol, bevantolol, bucomolol, bupranolol, butidrine, bunitolol, bunolol, butocrolol, butoamine, carazolol, carteolol, exaprolol, indenolol, iprocrolol, labetolol, mepindolol, metipranolol, metaprolol, moprolol, nadolol, nifenalol, oxprenolol, pamatolol, paragolol, penbutolol, pindolol, practolol, procinolol, pronethalol, propranolol, sotalol, tazolol, tiprenolol, tolamolol, tolamolol, befunolol, esmalol, hepunolol, celiprolol, azotinolol, diacetalol, acebutolol, salbutanol and isoxaprolol.

add  $b^{4}$  add add

W

1]/